| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/07/2009 | CA2372384C Anti-inflammatory bioactive glass particulates |
| 04/07/2009 | CA2341968C Pyrrolobenzodiazepine compounds |
| 04/07/2009 | CA2341471C Pyrrolbenzodiazepines |
| 04/07/2009 | CA2339253C Inhibitors of p38 |
| 04/07/2009 | CA2313704C Recombinant nodavirus compositions and methods |
| 04/07/2009 | CA2300424C Hiv nuclear localization inhibitors |
| 04/07/2009 | CA2281133C Multiple-agents-binding compound and use thereof |
| 04/07/2009 | CA2264488C A method for generating birnavirus from synthetic rna transcripts |
| 04/07/2009 | CA2237157C Cyclopeptolide inhibitors of adhesion molecules |
| 04/07/2009 | CA2217737C Thf-containing sulfonamide inhibitors of aspartyl protease |
| 04/07/2009 | CA2204652C Composition for prevention and treatment of hiv-1 infection comprising at least two different hiv-1 reverse transcriptase inhibitors |
| 04/07/2009 | CA2175332C Haemophilus transferrin receptor genes |
| 04/02/2009 | WO2009042589A1 Monoclonal antibodies to respiratory syncytial virus and uses thereof |
| 04/02/2009 | WO2009042395A1 Compositions comprising quinolone and methods for treating or controlling infections |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041570A1 Polymer conjugate of steroid |
| 04/02/2009 | WO2009041566A1 Preventive or remedy for posterior eye diseases containing quinazolinone derivative or quinoxaline derivative as the active ingredient |
| 04/02/2009 | WO2009041565A1 Quinazolinone derivative, and prophylactic or therapeutic agent for corneal/conjunctival disorder comprising quinazolinone derivative as active ingredient |
| 04/02/2009 | WO2009040755A2 Pyrrole compounds as inhibitors of mycobacteria, synthesis thereof ans intermediates thereto |
| 04/02/2009 | WO2009040754A2 Polymorphs of s-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1h,5h-benzo[i,j]quinolizine-2-carboxylic acid lysine salt |
| 04/02/2009 | WO2009040552A2 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof |
| 04/02/2009 | WO2009040507A1 Substituted benamidines as antibacterial agents |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040087A2 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040083A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040073A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040072A2 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040071A2 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040070A2 Use of helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040068A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040067A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040051A2 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 04/02/2009 | WO2009040050A2 Use of calcitonin as anti-angiogenic agent |
| 04/02/2009 | WO2009040049A2 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents |
| 04/02/2009 | WO2009040048A2 Use of the c-reactive peptide as a therapeutic agent |
| 04/02/2009 | WO2009040047A2 Therapeutic uses of ghrelin and combinations with stresscopin |
| 04/02/2009 | WO2009040046A2 Use of stresscopin-related peptide as a therapeutic agent |
| 04/02/2009 | WO2009040045A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| 04/02/2009 | WO2009040036A2 Use of a galanin peptide as a therapeutic agent |
| 04/02/2009 | WO2009040035A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040034A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040033A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040032A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040031A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040030A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040029A2 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040028A2 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009040025A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 04/02/2009 | WO2009040024A2 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections |
| 04/02/2009 | WO2009040023A2 Use of galnon as a therapeutic agent |
| 04/02/2009 | WO2009040022A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040021A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040020A1 Amylin as a therapeutic agent |
| 04/02/2009 | WO2009040019A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040018A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040017A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040006A1 Spantide for therapeutic uses |
| 04/02/2009 | WO2009040005A2 Use of the peptide rfmwmr as a therapeutic agent |
| 04/02/2009 | WO2009040004A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039996A2 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent |
| 04/02/2009 | WO2009039995A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039994A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039993A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039992A2 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039991A2 Use of aviptadil as a therapeutic agent |
| 04/02/2009 | WO2009039990A2 Use of icam peptide as a therapeutic agent |
| 04/02/2009 | WO2009039989A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | WO2009039988A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 04/02/2009 | WO2009039987A1 Use of peptide thr-thr-ser-gln-val-arg-pro-arg as a therapeutic agent |
| 04/02/2009 | WO2009039986A2 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 04/02/2009 | WO2009039985A2 Therapeutic uses of urocortin ii |
| 04/02/2009 | WO2009039984A2 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 04/02/2009 | WO2009039983A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039982A2 Use of gip alone or in combination with dynorphin b as a therapeutic agent |
| 04/02/2009 | WO2009039981A2 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039980A2 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039979A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | WO2009039977A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection |
| 04/02/2009 | WO2009039976A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039974A2 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039973A2 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039971A2 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents |
| 04/02/2009 | WO2009039970A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | WO2009039969A2 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 04/02/2009 | WO2009039968A2 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039966A2 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039963A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | WO2009039960A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009039957A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| 04/02/2009 | WO2009039731A1 Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof |
| 04/02/2009 | WO2009021971A3 Novel targets and compounds for therapeutic intervention of hiv infection |
| 04/02/2009 | WO2009019721A3 Quercetin derivatives as anti-cancer agents |
| 04/02/2009 | WO2009019553A3 Imidazopyridinones |